Efficacy and safety of finerenone according to frailty in patients with heart failure: a prespecified analysis of the FINEARTS-HF trial

Back

HFA Premium Access

Efficacy and safety of finerenone according to frailty in patients with heart failure: a prespecified analysis of the FINEARTS-HF trial

Session: Inflammation, frailty, and vascular function: exploring prognostic and therapeutic strategies

Topic: Comorbidities

Speaker: Doctor J. Butt (Copenhagen, DK)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

2 presentations

0 follower

5 more presentations in this session

Exploring the overlap: prevalence and predictors of orthostatic hypotension in heart failure

Speaker: Doctor P. Bernardes (Setubal, PT)

Sex differences of inflammatory drivers of muscle wasting in patients with heart failure with reduced ejection fraction

Speaker: Doctor A. Tinggaard (Aarhus, DK)

Skeletal muscle structural changes in patients with heart failure with reduced ejection fraction: a one-year longitudinal study

Speaker: Mr O. Ziga (Aarhus, DK)

Frailty, inflammation, prognosis and thyroid hormones in heart failure: the clinical relevance of the FT3/FT4 ratio

Speaker: Assistant Professor C. Okoye (Milan, IT)

Aerobic exercise training and AAV9-mediated miRNA-205 delivery prevent metabolic and phenotypic skeletal muscle changes induced by heart failure

Speaker: Mr B. Pelozin (Sao Paulo, BR)

Access the full session

Inflammation, frailty, and vascular function: exploring prognostic and therapeutic strategies

Speakers: Doctor J. Butt, Doctor P. Bernardes, Doctor A. Tinggaard, Mr O. Ziga, Assistant Professor C. Okoye...

Access

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources